Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols
Many individuals report feeling benefits such as improved hydration, energy, or mental clarity within minutes to hours after treatment, with effects that may last several days depending on the formulation used
al-Kabban, M
Cht lng sn phm ok thch Dng Tho Vy mua ti rocy.vn c xp hng 5 5 sao Gi hng quas cn thn, t vn mua hng rt nhit tnh v c c 1 bn chm sc kh na
Samples were washed and subsequently incubated with secondary antibody for 45 min at RT (Table 3) Sections were counterstained either with the diaminobenzidine substrate kit (Nacalai, USA) followed by hematoxylin, or sections were stained with 6-diamidino-2-phenylindole (DAPI, Thermo Fisher, USA) for visualization of cell nuclei as previously described
